首页> 美国卫生研究院文献>other >CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers
【2h】

CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

机译:针对三阴性乳腺癌的CXCR4靶向纳米载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis-(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.
机译:CXCR4是一种细胞膜受体,在三阴性乳腺癌中过表达,并且与这种疾病的生长和转移有关。使用电动流体动力喷射技术,我们为CXCR4靶向制备了多室药物递送载体。颗粒由新型的聚(丙交酯-共-乙交酯)衍生物组成,可直接固定1,1'-[1,4-亚苯基双-(亚甲基)]双[1,4,8,11-四氮杂环十四烷] (Plerixafor),一种对CXCR4具有亲和力的小分子。靶向的纳米载体被表达CXCR4的细胞选择性吸收,并有效阻断CXCR4信号传导。这项研究表明CXCR4可能是基于纳米载体的疗法的有效靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号